Mr Birendra Kumar David, CTO, Graviti Pharmaceuticals

Speaker in this video:
Mr Birendra Kumar David, CTO, Graviti Pharmaceuticals

Topic: Beyond the vial: The evolution of injectable delivery devices

Key Highlights:
[1] Pre-filled syringes, auto-injectors, and pens are rapidly replacing vials, now accounting for ~55 per cent of the market.

[2] Home healthcare, self-administration, and safety concerns are accelerating adoption of easy-to-use injectable devices.

[3] Biologics and GLP-1 therapies are key growth engines. High-growth therapies (mAbs, biosimilars, GLP-1) are predominantly designed for subcutaneous, device-based delivery.

[4] Success depends on integrating device design, fill-finish capability, and supply chain complexity from the start.